|
|
|
| Expression and Significance of VEGF and MVD in Patients with Placental Implantation Complicated by Infection |
| JIN Fengmei, et al |
| Chengde Central Blood Station, Hebei Chengde 067000, China |
|
|
|
|
Abstract Objective: To explore the relationship between vascular endothelial growth factor (VEGF), placental microvessel density (MVD) and postpartum placental accretacomplicated with infection. Methods: Placental tissue and fasting venous blood were taken as samples of 535 pregnant women with placental accretain admitted to our hospital from September 2011 to February 2021. Real-time quantitative reverse transcription polymerase chain reaction (RT-qPCR), enzyme-linked immunosorbent test (ELISA), western blotting (WB) test and immunohistochemistry were used to detect the expression of VEGF protein, VEGF mRNA and MVD in placental tissue and serum. Pearson correlation was used to analyze the relationship between VEGF and MVD. Results: Compared with the placenta accreta without complicated infection group, the proportion of patients over 35 years old, the proportion of cesarean section times ≥ 1 and the proportion of induced abortion times ≥ 2 patients in the placenta accreta complication group were higher (χ2=80. 558, 82. 320, 116. 681, P<0. 001), and the mRNA, protein expression and serum content of VEGF were significantly increased (t = 22. 834, 15. 575, 7. 862, P<0. 001), and the MVD value was also significantly increased (t = 10. 096, P<0. 001). Pearson correlation analysis showed that the content of VEGF in placenta was positively correlated with MVD value (r=0. 645, P<0. 001). Conclusion: The expression of VEGF and MVD increased in placenta accreta complicated with infection, which was positively correlated with placenta accreta complicated infection, and VEGF content was positively correlated with MVD value in infected placenta, which could be used as the basis for the treatment of placenta accreta complicated with infection.
|
|
|
|
|
|
[1] Cahill AG,Beigi R,Heine RP,et al.Placenta accretaspectrum[J].Am ObstetGynecol,2018,219(6):B2-B16.
[2] Carusi DA,Fox KA,Lyell DJ,et al.Placenta accretaspectrum without placenta Previa[J].ObstetGynecol,2020,136(3):458-465.
[3] Duzyj CM,Cooper A,Mhatre M,et al.Placenta accreta:a spectrum of predictable risk,diagnosis,and morbidity[J].Am Perinatol,2019,36(10):1031-1038.
[4] Cal M,Ayres-de-Campos D,Jauniaux E.International survey of practices used in the diagnosis and management of placenta accreta spectrum disorders[J].International journal of gynaecology and obstetrics:the official organ of the International Federation of Gynaecology and Obstetrics,2018,140(3):307-311.
[5] 周冰峰,阚长利,侯敬,等.孕妇血清VEGF和sFlt-1联合多普勒超声诊断胎盘植入效果[J].中国计划生育学杂志,2021,29(1):114-117.
[6] 曹泽毅.中华妇产科(临床版)[M].北京:人民卫生出版社,2013.229.
[7] 乔小改,蔡大军.凶险性前置胎盘组织中HMGB1蛋白表达及其与胎盘植入的关系研究[J].实用妇产科杂志,2020,36(2):136-140.
[8] McNally L,Zhou Y,Robinson JF,et al.Up-regulated cytotrophoblast DOCK4 contributes to over-invasion in placenta accreta spectrum[J].Proc Natl AcadSci U S A,2020,117(27):15852-15861.
[9] Matin M,Mrgelin M,Stetefeld J,et al.Affinity-enhanced multimeric VEGF (vascular endothelial growth factor) and PlGF (placental growth factor) variants for ppecificadsorption of sFlt-1 to restore angiogenicbalance in preeclampsia[J].Hypertension,2020,76(4):1176-1184.
[10] Guo X,Yi H,Li TC,et al.Role of vascular endothelial growth factor (VEGF) in human embryo implantation:Clinical implications[J].Biomolecules,2021,11(2):253.
[11] 柳月霞,王东旭,魏菊红,等.妊娠晚期母体血清VEGF、PlGF和sFlt-1对胎盘植入性疾病的预测价值[J].中国计划生育学杂志,2019,27(11):134-137. |
|
|
|
2022, Vol. 28 
